H2 Equity Partners is pleased to announce its fifth investment by Fund V: parallel investments in Healthcare 21 and Aquilant with the aim to create a new market-leading group in healthcare and scientific sales & distribution – partnering with the shareholders of Healthcare 21.
H2 Equity Partners recently completed the acquisition of Aquilant and has reached agreement to invest in Healthcare 21 Group with the aim to facilitate the creation of a new market-leading group consisting of Aquilant and Healthcare 21. The envisaged transaction is subject only to Competition Authority approval – and is expected to complete by the end of September 2018.
The combined companies will have a turnover in excess of €150 million and employ 450 people across Ireland, the UK, Germany and Austria. The businesses complement each other extremely well and the combined group offers an expanded product portfolio in many exciting therapy areas. In addition, the combined group’s infrastructure and expertise will ensure that both companies can maintain focus on their current plans and continue to deliver world class outcomes for their customers and suppliers alike.
Healthcare 21, Aquilant and H2 Equity Partners expect to accelerate the growth of the combined group as we drive to become Europe’s largest and best-in-class provider of outsourced sales, marketing and service solutions for the new group’s suppliers and customers.